Compass Pathways' depression treatment meets main goal in late‑stage study
17/02/2026 11:37
Feb 17 (Reuters) - Drug developer Compass Pathways CMPS.O said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study. (Reporting by Sahil Pandey in Bengaluru; Editing by Devika Syamnath) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications